免疫评分的研究进展

doi:10.3760/cma.j.issn.1673-422X.2016.10.012

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (10): 772-774.doi: 10.3760/cma.j.issn.1673-422X.2016.10.012

免疫评分的研究进展

赵新茹,赵玉叶,李国洪,阚璇,牛作兴

50022 济南大学山东省医学科学院医学与生命科学学院（赵新茹、阚璇）；山东省肿瘤医院内科（赵新茹、牛作兴）；山东省邹城市中医院肛肠科（赵玉叶）；山东省枣庄市峄城区中医院肿瘤科（李国洪）

出版日期:2016-10-08 发布日期:2016-09-07
通讯作者: 牛作兴 E-mail:791416966@qq.com

Research progress of immunoscore

Zhao Xinru, Zhao Yuye, Li Guohong, Kan Xuan, Niu Zuoxing

School of Medicine and Life Science, University of Ji′nan and Shandong Academy of Medical Sciences; Department of Internal Medicine, Shandong Cancer Hospital, Ji′nan 250022, China

Online:2016-10-08 Published:2016-09-07
Contact: Niu Zuoxing E-mail:791416966@qq.com

摘要/Abstract

摘要： 学者们在关注肿瘤组织免疫特性的基础上提出了一种名为“免疫评分”的肿瘤预测预后新方法，已被证明是一种优于国际抗癌联盟美国癌症联合委员会（UICCAJCC）TNM分期的预后因素，近年来已有其应用于结直肠癌等肿瘤的相关报道。该方法操作简单，花费低，且准确性高，可用于指导个体化治疗，但要成为临床常规检测指标仍有其局限性。

关键词: 肿瘤分期, 预后, 免疫评分

Abstract: A methodology named "immunoscore" has been proposed in recent years. It has been demonstrated to be a prognostic factor superior to the Union for International Cancer ControlAmerican Joint Committee on Cancer (UICCAJCC) TNM classification. Over the past few years, it has gained a forefront position in colorectal cancer. It has the advantages of simple operation, low cost and high accuracy, and it is needed for individual therapy. However, it still has its limitations.

Key words: Neoplasm staging, Prognosis, Immunoscore

赵新茹,赵玉叶,李国洪,阚璇,牛作兴. 免疫评分的研究进展[J]. 国际肿瘤学杂志, 2016, 43(10): 772-774.

Zhao Xinru, Zhao Yuye, Li Guohong, Kan Xuan, Niu Zuoxing. Research progress of immunoscore[J]. Journal of International Oncology, 2016, 43(10): 772-774.

参考文献

［1］ Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologicbased prognostic factors of colorectal cancers are associated with the state of the local immune reaction［J］. J Clin Oncol, 2011, 29(6): 610-618. DOI: 10.1200/JCO.2010.30.5425. ［2］孙成, 田志刚. 免疫评分:依据肿瘤组织免疫特性进行预后预测［J］. 中国肿瘤生物治疗杂志, 2015, 22(2): 177-182. DOI: 10.3872/j.issn.1007385X.2015.02.006. ［3］ Mlecnik B, Bindea G, Pagès F, et al. Tumor immunosurveillance in human cancers［J］. Cancer Metastasis Rev, 2011, 30(1): 5-12. DOI: 10.1007/s1055501192707. ［4］ Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care?［J］. Nat Rev Clin Oncol, 2012, 9(2): 119-123. DOI: 10.1038/nrclinonc.2011.157. ［5］ Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation［J］. Cell, 2011, 144(5): 646-674. DOI: 10.1016/j.cell.2011.02.013. ［6］ Zlobec I, Bihl M, Foerster A, et al. Comprehensive analysis of CpG island methylator phenotype (CIMP)high, low, and negative colorectal cancers based on protein marker expression and molecular features［J］. J Pathol, 2011, 225(3): 336-343. DOI: 10.1002/path.2879. ［7］ Laghi L, Malesci A. Microsatellite instability and therapeutic consequences in colorectal cancer［J］. Dig Dis, 2012, 30(3): 304-309. DOI: 10.1159/000337003. ［8］ Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ′immunoscore′ in the classification of malignant tumours［J］. J Pathol, 2014, 232(2): 199-209. DOI: 10.1002/path.4287. ［9］ Ingels A, Sanchez Salas RE, Ravery V, et al. Thelper 1 immunoreaction influences survival in muscleinvasive bladder cancer: proof of concept［J］. Ecancermedicalscience, 2014, 8: 486. DOI: 10.3332/ecancer.2014.486. ［10］ Van Den Boorn JG, Hartmann G. Turning tumors into vaccines: coopting the innate immune system［J］. Immunity, 2013, 39(1): 27-37. DOI: 10.1016/j.immuni.2013.07.011. ［11］ Angell H, Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer［J］. Curr Opin Immunol, 2013, 25(2): 261-267. DOI: 10.1016/j.coi.2013.03.004. ［12］ Galon J, Pagès F, Marincola FM, et al. Cancer classification using the immunoscore: a worldwide task force［J］. J Transl Med, 2012, 10(1): 205. DOI: 10.1186/1479587610205. ［13］ Fridman WH, Pagès F, SautèsFridman C, et al. The immune contexture in human tumours: impact on clinical outcome［J］. Nat Rev Cancer, 2012, 12(4): 298-306. DOI: 10.1038/nrc3245. ［14］ Galon J, Pagès F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer［J］. J Transl Med, 2012, 10(1): 1. DOI: 10.1186/14795876101. ［15］ Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma［J］. Clin Cancer Res, 2013, 19(5): 1225-1231. DOI: 10.1158/10780432.CCR121630. ［16］黄莹莹, 高晨燕. 免疫法治疗肿瘤的疗效评价的思考［J］. 中国临床药理学杂志, 2015, 31(13): 1338-1340. DOI: 10.13699/j.cnki.10016821.2015.13.037. ［17］ Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiPDL1 antibody in patients with advanced cancer［J］. N Engl J Med, 2012, 366(26): 2455-2465. DOI: 10.1056/NEJMoa1200694. ［18］ Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma［J］. N Engl J Med, 2011, 364(26): 2517-2526. DOI: 10.1056/NEJMoa1104621. ［19］ Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiPD1 antibody in cancer［J］. N Engl J Med, 2012, 366(26): 2443-2454. DOI: 10.1056/NEJMoa1200690. ［20］ Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer［J］. Immunity, 2013, 39(4): 782-795. DOI: 10.1016/j.immuni.2013.10.003.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[5]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[6]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[7]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[8]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[9]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[10]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[11]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[12]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[13]	黄镇, 陈永顺. 循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[14]	王潇, 李盈, 罗玉杰, 晋舒. 基于列线图模型探讨血清学指标对鼻咽癌预后的判断价值[J]. 国际肿瘤学杂志, 2023, 50(8): 463-469.
[15]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.

免疫评分的研究进展

Research progress of immunoscore

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价